Clinical Trials Logo

Small Cell Lung Cancer Recurrent clinical trials

View clinical trials related to Small Cell Lung Cancer Recurrent.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05815160 Recruiting - Clinical trials for Small Cell Lung Cancer Recurrent

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Start date: May 2, 2023
Phase: Phase 1
Study type: Interventional

The primary purpose of part 1 (dose escalation) of this study is to identify the recommended phase 2 dose (RP2D) and to characterize the safety and tolerability of Debio 0123 in combination with carboplatin and etoposide. The primary purpose of part 2 (dose expansion) of this study is to characterize the safety and tolerability of Debio 0123 at the RP2D when administered in combination with carboplatin and etoposide.

NCT ID: NCT03994744 Recruiting - Clinical trials for Small-cell Lung Cancer

Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC

Start date: August 20, 2019
Phase: Phase 2
Study type: Interventional

In this Single arm study, histologically or cytologically confirmed ED-stage small cell lung cancer (SCLC) patients resistant to or relapsed after standard chemotherapy will be enrolled to investigate the Efficacy and Safety of a Combination of Sintilimab and Metformin. Primary outcome: Objective response rate (ORR), Safety of the combination therapy Secondary outcome: Overall survival (OS), Progression-free survival (PFS), Duration of response(DOR),

NCT ID: NCT03262454 Recruiting - Clinical trials for Small Cell Lung Cancer Recurrent

Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC

Atezolizumab
Start date: January 22, 2018
Phase: Phase 2
Study type: Interventional

The investigators hypothesized that local radiation therapy can enhance the effect of anti-PD-L1 monoclonal antibody through priming T-cell effector function against cancer cells. Described as above, The investigators concluded that modest dose of radiation to local site prior to immunotherapy is the best to enhance T-cell-mediated immunity. Accordingly, The investigators will investigate the combining effect of hypofractionated-sublethal dose of radiation therapy followed by anti-PD-L1 monoclonal antibody, atezolizumab, for SCLC patients who are recurrent or refractory for initial platinum-based chemotherapy